Details
-
Change Request
-
Resolution: Unresolved
-
Highest
-
FHIR Core (FHIR)
-
R5
-
Clinical Decision Support
-
STU
-
Evidence
Description
We suggest adding the two elements to the Evidence resource: funding source; (ii) IRB entity.
We suggest the following additions to the StudyDesign value set: case series; (ii) blinding of data collectors; (iii) types of allocation concealment, such as sealed envelope, sequential numbered envelope and centralized; (iv) intention-to-treat analysis type; (v) per-protocol analysis type.
We suggest the following additions to the StatisticType value set: area under the receiver operating characteristic curve; (ii) mode; (iii) percentage.
We suggest adding "High loss to follow up" to the EvidenceCertaintyType value set.
Attachments
Issue Links
- is voted on by
-
BALLOT-41787 Negative - Howard Strasberg : 2022-Sep-FHIR R5 STU
- Closed
-
BALLOT-43724 Negative - Barbara Atkins : 2022-Sep-FHIR R5 STU
- Closed
-
BALLOT-43853 Negative - Bonnie Briggs : 2022-Sep-FHIR R5 STU
- Closed
-
BALLOT-43966 Negative - Jeremy Kasmann : 2022-Sep-FHIR R5 STU
- Closed
- relates to
-
FHIR-39601 Add irb-entity to Research Study Party Role value set
-
- Published
-
- mentioned in
-
Page Loading...